AstraZeneca: Enhertu Granted Priority Review in the US for Patients With HER2-Low or HER2-Ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy
October 02, 2024
October 02, 2024
WILMINGTON, Delaware, Oct. 2 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Based on DESTINY-Breast06 Phase III trial which demonstrated a statistically significant and clinically meaningful progression-free survival benefit for ENHERTU
If approved, AstraZeneca and Daiichi Sankyo's ENHERTU will be the first HER2 directed therapy and ADC for patients prior to receiving chemotherapy for metastatic breast ca . . .
* * *
Based on DESTINY-Breast06 Phase III trial which demonstrated a statistically significant and clinically meaningful progression-free survival benefit for ENHERTU
If approved, AstraZeneca and Daiichi Sankyo's ENHERTU will be the first HER2 directed therapy and ADC for patients prior to receiving chemotherapy for metastatic breast ca . . .